Download Xcovery to Present at the ASCO Annual Meeting 2016

FINAL
Xcovery to Present at the ASCO Annual Meeting 2016
Palm Beach Gardens, Fla., and Needham, Mass., June 1, 2016 – Xcovery, a developer of targeted
therapeutics for cancer, today announced that data on the plasma genotyping of patients enrolled in its
expansion Phase I/II trial of ensartinib (X-396), the Company’s lead ALK inhibitor drug candidate, in
patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) will be
presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016, which is being held
from June 3 - 7, 2016 in Chicago, Illinois. The presentation details are as follows:
Poster Title: Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients
(pts) with ALK+ non-small cell lung cancer (NSCLC)
Poster Session: Lung Cancer – Non-Small Cell Metastatic
Poster Time: Sunday, June 5, 2016 from 8:00am - 11:30am CDT
Session Location: McCormick Place, Hall A
Poster Board Number: 379
Abstract Number: 9056
Presented by: Leora Horn, MD, MSc, Vanderbilt University Medical Center
Additional abstract details can be found at abstracts.asco.org.
About Ensartinib (X-396)
Xcovery’s lead asset is Ensartinib (X-396), a small molecule, anaplastic lymphoma kinase (ALK) inhibitor.
It is being studied in the eXalt2 Study, a Phase II trial for the treatment of ALK-positive non-small cell
lung cancer (NSCLC). The eXalt2 Study is currently enrolling patients. To learn more, visit:
www.xalt2study.com or ClinicalTrials.gov under trial identifier NCT01625234.
About NSCLC and ALK
Lung cancer is the second most common type of cancer identified in the United States with an
estimated 221,000 new diagnoses expected in 2015. Non‐small cell lung cancer (NSCLC) is the most
common type of lung cancer, accounting for an estimated 85‐90% of the lung cancer cases. The
anaplastic lymphoma kinase (ALK) gene is located on chromosome 2 and rearrangement of the ALK
gene can lead to its activation or expression, therefore increasing a person’s chance of developing
certain types of cancer, including NSCLC. Between three and seven percent of patients with NSCLC have
the ALK rearrangement, making this a molecular target warranting investigation for NSCLC patients.
About Xcovery
Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by
discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies
to target a wide range of advanced tumors. For more information, visit www.xcovery.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on company management’s
current beliefs and expectations and are subject to currently unknown information, risks and
circumstances and actual results may vary from what is being currently projected.
###
Company Contact:
Michael Webb
Xcovery President and Chief Executive Officer
(857) 202-3911
[email protected]
Media Contact:
Julia Ogier
MacDougall Biomedical Communications
(781) 235-3060
[email protected]